MEDICINOVA JAPAN
Obtained a degree from the Faculty of Law, The University of Tokyo From September 2004 to January 2010 Director of the Company , working for the Development Bank of Japan (currently Development Bank of Japan) since 1980 2006 Director of the New Development Department, Development Bank of Japan (lending to venture companies)・ Investment / Fund formation, VC management) June 2008 General Manager of Management Strategy Department, SG Holdings Co., Ltd. June 2009 Representative Director, Sagawa Financial Co., Ltd. January 2012 Director , Sagawa Global Logistics Co., Ltd. April 2013 President and Representative Director of SG Asset Max Co., Ltd. Audit & Supervisory Board Member of Sagawa Advance Co., Ltd. and SG System Co., Ltd. from March 2017
MEDICINOVA JAPAN
Industry:
Chemical Medical
Founded:
2000-09-26
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.medicinova.jp
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
White Mountain
White Mountain specializes in the development of systems for the medical industry.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.medicinova.jp
- Host name: sv240.xbiz.ne.jp
- IP address: 183.90.231.41
- Location: Osaka Japan
- Latitude: 34.6848
- Longitude: 135.5142
- Timezone: Asia/Tokyo
- Postal: 543-0062
More informations about "MediciNova japan"
MediciNova,Inc | Patients voice. Our choice. 笑顔のために・・・
Dec 3, 2021 · MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders: 2024/10/31 MN-166 ALS ...See details»
Home - MediciNova, Inc.
MediciNova is a biopharmaceutical company that is developing novel therapeutics with a primary focus on neurology, respiratory, and liver diseases with unmet medical needs.See details»
会社概要 | MediciNova,Inc
Nov 15, 2024 · 商号MediciNova, Inc.（メディシノバ・インク）設立年月日2000年9月26日資本の部62,378,424米ドル（2023年12月末時点）事業内容医療用医薬品のライ...See details»
企業情報 | MediciNova,Inc
Sep 24, 2021 · トップメッセージ 理念・経営方針 会社概要 経営メンバー 沿革 コーポレートガバナンスSee details»
Company - MediciNova, Inc.
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet …See details»
Corporate Profile | MediciNova, Inc.
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet …See details»
MediciNova - Crunchbase Company Profile & Funding
MediciNova is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market.See details»
MediciNova History - MediciNova, Inc.
MediciNova, Inc. was founded in September 2000 with $10 million in Series A seed funding from Tanabe Seiyaku Co., Ltd. (Osaka). MediciNova was established in San Diego as a …See details»
Investor Home - MediciNova, Inc.
Nov 21, 2024 · MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with …See details»
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter …
MediciNova Founder, CEO and President About MediciNova MediciNova , Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule …See details»
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter …
LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of …See details»
MediciNova Announces Presentation of Results from the Phase 2b …
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative …See details»
Corporate Presentation - MediciNova
Mar 12, 2021 · MediciNova, Inc. is a publicly-traded, development-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of diseases with high …See details»
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter …
Nov 19, 2024 · MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and …See details»
MediciNova, Inc. Company Profile | La Jolla, CA | Competitors ...
Find company research, competitor information, contact details & financial data for MediciNova, Inc. of La Jolla, CA. Get the latest business insights from Dun & Bradstreet.See details»
MediciNova Announces Data from Phase 1b/2a Clinical Trial of …
Jun 3, 2024 · MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and …See details»
現在進行中の臨床治験 | MediciNova,Inc
Apr 16, 2024 · MediciNova, Inc.の現在進行中の臨床治験について紹介しています。See details»
MediciNova to Present at the J.P. Morgan Healthcare Conference …
Oct 4, 2018 · MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with …See details»
MediciNova, Inc. (MNOV) - Yahoo Finance
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.See details»
MediciNova Announces SARS-CoV-2 Vaccine Joint Development …
Jul 27, 2020 · MediciNova has been granted exclusive worldwide development rights to use BC-PIV for SARS-CoV-2 vaccine development from BioComo and Mie University. BC-PIV, an …See details»